Sorafenib is a multikinase inhibitor for the treatment of hepatocellular carcinoma. However,
most patients who initially respond to sorafenib become refractory. In a previous study, we …

Sorafenib is a small, orally‐active multikinase inhibitor that is most frequently used for the
management of renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine …

We investigated the mechanism and effects of sorafenib on hepatic stellate cell (HSC)
viability and in the liver tumor microenvironment. The expression of α-smooth muscle actin …

Sorafenib is the standard systemic treatment for patients with advanced hepatocellular
carcinoma (HCC); however, its therapeutic value in patients with HCC following resection …

Sorafenib, an oral multiple kinase inhibitor, is the standardized treatment for hepatocellular
carcinoma (HCC). One strategy to improve HCC therapy is to combine agents that target key …

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …

Background We investigated the contribution of subsequent therapy for advanced
hepatocellular carcinoma refractory or intolerant to sorafenib. Further, we investigated the …

Objective. To explore the efficacy of sorafenib combined with interventional therapy on
primary liver cancer (PLC) patients and its effect on serum AFP, VEGF, and GGT. Methods …

Sorafenib, a multikinase inhibitor targeting angiogenesis, cell survival, and proliferation in
hepatocellular carcinoma (HCC) is a standard therapy for advanced stage disease …

Background Sorafenib has been approved in the indication of unresectable hepatocellular
carcinoma, but there are many cases in which administration of the drug is discontinued due …